Yu Cong, Cao Jiamin, Xie Xiaodong, Chen Wenguang, Hong Ensi
Graduate School, Jiangxi University of Traditional Chinese Medicine Nanchang, Jiangxi, China.
Nanchang Normal University, Infirmary of the Logistics Support Department, Nanchang, Jiangxi, China.
Front Oncol. 2025 Jul 17;15:1537508. doi: 10.3389/fonc.2025.1537508. eCollection 2025.
JAK1, a member of the JAK kinase family, is involved in the signal transduction of multiple cytokine pathways and is crucial in the onset and progression of inflammation and tumours. Consequently, JAK1 has garnered significant attention in recent years.
We use bibliometric and visual analysis to evaluate the thematic trends and knowledge structure of TRPV1's research papers on JAK1, sourced from the Web of Science core collection from 2003 to 2024. CiteSpace is used to analyze references and keywords of authors, institutions, countries, and commonly cited, and applies co-current and clustering functions to generate visual knowledge maps.
A total of 3,686 articles were incorporated. The primary research domain of JAK1 is oncology; the United States leads in publication volume, with the University of Texas holding the most prominent central position. The keyword distribution indicates that the literature on JAK1 from 2003 to 2009 primarily concentrated on mechanistic studies, encompassing gene expression, activation, pathways, and cell apoptosis. From 2008 to 2018, research hotspots predominantly examined the association between JAK1 and various disease atlases. Beginning in 2012 and extending to 2024, the focus shifted towards the research and development of clinical pharmaceuticals, along with their safety and efficacy. Gene expression, signal transduction, atopic dermatitis, and JAK1-selective inhibitors have emerged as prominent research areas in recent years, exhibiting significant potential for development.
This study presents the contemporary status and prospective trends of JAK1 research over the last two decades. Current research focuses on skin inflammation, rheumatoid arthritis, and tumor-related diseases, while new signaling pathways are constantly being discovered. JAK1 inhibitors are gradually being used in clinical practice and have good development prospects, which will become the main trend of future research.
JAK1是JAK激酶家族的成员之一,参与多种细胞因子途径的信号转导,在炎症和肿瘤的发生发展中起关键作用。因此,近年来JAK1受到了广泛关注。
我们运用文献计量学和可视化分析方法,对2003年至2024年来自科学网核心合集的关于JAK1的TRPV1研究论文的主题趋势和知识结构进行评估。使用CiteSpace分析作者、机构、国家的参考文献和关键词以及共被引情况,并应用共现和聚类功能生成可视化知识图谱。
共纳入3686篇文章。JAK1的主要研究领域是肿瘤学;美国在发文量上领先,德克萨斯大学处于最突出的中心位置。关键词分布表明,2003年至2009年关于JAK1的文献主要集中在机制研究,包括基因表达、激活、途径和细胞凋亡。2008年至2018年,研究热点主要是考察JAK1与各种疾病图谱之间的关联。从2012年开始至2024年,重点转向临床药物的研发及其安全性和有效性。基因表达、信号转导、特应性皮炎和JAK1选择性抑制剂近年来已成为突出的研究领域,展现出显著的发展潜力。
本研究呈现了过去二十年JAK1研究的现状和未来趋势。当前研究聚焦于皮肤炎症、类风湿关节炎和肿瘤相关疾病,同时不断有新的信号通路被发现。JAK1抑制剂正逐渐应用于临床实践且具有良好的发展前景,这将成为未来研究的主要趋势。